PECULIARITIES OF CARDIOVASCULAR OUTCOMES IN MALE AND FEMALE PATIENTS AFTER NOVEL CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Currently, the effects of COVID-19 at cardiovascular system condition in young and middle-aged people, depending on gender, are of profound interest. The aim of the study is to evaluate cardiovascular outcomes in male and female patients after COVID-19 infection. Material and methods. 658 patients aged 25-59 years and underwent a preventive medical examination were included in open comparative study. Depending on the presence or absence of COVID-19 history in anamnesis, they were divided into the main group (n=416, median age 40 (33; 47) years) and the comparison group (n=242, median age 41 (34; 47) years). The main group included 361 (86,8%) females and 55 (13,2%) males, the comparison group included 197 (81,4%) females and 45 (18,6%) males (p=0,083). Demographic indicators, risk factors, cardiovascular risk (CVR) were assessed. A year later, the abovementioned indicators, incidence of COVID-19 and new cases of arterial hypertension (AH), coronary artery disease, and diabetes mellitus were re-registered. Results. After previous COVID-19, arterial hypertension was first diagnosed in 8% (p=0,001) of female and 14,6% (p=0,058) of male patients. A higher incidence in females with overweight (78,1%; p=0,001), hyperglycemia (52%; p=0,001) and moderate cardiovascular risk (61,7%; p=0,008) was fixed. The number of females with high (p=0,037) and very high CVR (p=0,037) increased, and the number of females with low CVR decreased (p=0.001). After previous COVID-19, all male smokers quit smoking (p<0.001), while the number of men with overweight (89%; p=0,001) and very high CVR (25,4%; p=0,002) increased. IHD was diagnosed in 2,8% (p=0,082) of females and 7,2% of males (p=0,126), diabetes mellitus in 3,9% (p=0,012) of females and 5,4% of males (p=0,434) within a median of 3 (2; 4) months after suffering from COVID-19. Conclusion. Females aged 25 to 59 years old with moderate CV risk, overweight, smoking, 3 or more cardiovascular disease (CVD) risk factors, and males of similar age with 3 or more CVD risk factors and smoking who have had COVID-19 infection, should cause medical alertness regarding CVD development.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Kirill Glibko

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; City Clinical Hospital No. 13 of the Department of Healthcare of Moscow

Email: glibkokv@zdrav.mos.ru
assistant at the Department of polyclinic therapy of the Faculty of general medicine; general practitioner 115280, Moscow, 1/1 Velozavodskaya Str

Sergei Arakelov

City Clinical Hospital No. 13 of the Department of Healthcare of Moscow; Peoples' Friendship University of Russia

Dr. med. habil., head of the Department of family medicine with a course of palliative care of the Faculty of continuing medical education 115280, Moscow, 1/1 Velozavodskaya Str

Irina Titova

City Clinical Hospital No. 13 of the Department of Healthcare of Moscow

deputy chief physician of the medical 115280, Moscow, 1/1 Velozavodskaya Str

Diana Kasaeva

City Clinical Hospital No. 13 of the Department of Healthcare of Moscow

head of the polyclinic 115280, Moscow, 1/1 Velozavodskaya Str

Vera Larina

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: larinav@mail.ru
Dr. med. habil., professor, head of the Department of polyclinic therapy of the Faculty of general medicine 117997, Moscow, 1 Ostrovityanova Str

Әдебиет тізімі

  1. Dhakal B.P., Sweitzer N.K., Indik J.H. et al. SARS-cov-2 Infection and cardiovascular disease: COVID-19 heart. Heart Lung Circ. 2020; 29(7): 973-87. https://dx.doi.Org/10.1016/j.hlc.2020.05.101
  2. Yang J., Zheng Y., Gou X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: A systematic review and meta-analysis.Int J Infect Dis. 2020; 94: 91-95. https://dx.doi.org/10.1016/j.ijid.2020.03.017
  3. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-42. https://dx.doi.org/10.1001/jama.2020.2648.
  4. Мелехов А.В., Агаева А.И., Никитин И.Г Симптоматика в отдаленном периоде после перенесенной коронавирусной инфекции: результаты длительного наблюдения. Архивъ внутренней медицины. 2022; 12(4): 302-309.
  5. Williamson E.J., Walker A.J., Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821): 430-36. https://dx.doi.org/10.1038/s41586-020-2521-4.
  6. Некаева Е.С., Большакова А.Е., Малышева Е.С. с соавт. Гендерные особенности новой коронавирусной инфекции (COVID-19) у лиц зрелого возраста. Современные технологии в медицине. 2021; 13(4): 16-26.
  7. Petrilli C.M., Jones S.A., Yang J. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ. 2020; 369: m1966. https://dx.doi.org/10.1136/bmj.m1966.
  8. Van Gerwen M., Alsen M., Little C. et al. Risk factors and outcomes of COVID-19 in New York City; A retrospective cohort study. J Med Virol. 2021; 93(2): 907-15. https://dx.doi.org/10.1002/jmv.26337.
  9. Mcpadden J., Warner F., Young H.P. et al. Clinical characteristics and outcomes for 7,995 patients with SARS-cov-2 infection. PLOS One. 2021; 16(3): e0243291. https://dx.doi.org/10.1371/journal.pone.0243291.
  10. Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. с соавт. Международный регистр «Анализ динамики Коморбидных заболеваний у пациентов, перенесших инфицирование SARS-cov-2» АКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал. 2021; 26(4): 116-131
  11. Бойцов С.А., Погосова Н.В., Бубнова М.Гссоавт. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 23(6): 7-122
  12. Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149-218
  13. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020; 23(S2): 4-102
  14. Лукьянов М.М., Кутишенко Н.П., Марцевич С.Ю. с соавт. Отдаленные исходы у больных, перенесших COVID-19 (данные регистра ТАРГЕТ-ВИП). Российский кардиологический журнал. 2022; 27(3): 60-66
  15. Ротарь О.П., Ерина А.М., Бояринова М.А. с соавт. Контроль артериальной гипертензии в период пандемии коронавирусной инфекции: результаты российской акции скрининга МММ2021. Российский кардиологический журнал. 2022; 27(4): 7-13
  16. Sudre C.H., Murray B., Varsavsky T. et al. Attributes and predictors of long COVID. Nat Med. 2021; 27(4): 626-31. https://dx.doi.org/10.1038/s41591-021-01292-y
  17. Арутюнов А.Г, Сеферович П., Бакулин И.Гссоавт. Реабилитация после COVID-19. Резолюция Международного совета экспертов Евразийской ассоциации терапевтов и Российского кардиологического общества. Российский кардиологический журнал. 2021; 26(9): 135-151
  18. Трисветова Е.Л. Синдром постуральной ортостатической тахикардии как проявление постковидного синдрома. Рациональная фармакотерапия в кардиологии. 2022; 18(2): 200-208
  19. Дворников А.С., Силин А.А., Гайдина Т.А. с соавт. Кожные проявления при коронавирусной болезни 2019 года (COVID-19). Архивъ внутренней медицины. 2020; 10(6): 422-429
  20. Вахненко Ю.В., Доровских И.Е., Домке А.П. Кардиоваскулярная составляющая постковидного синдрома. Тихоокеанский медицинский журнал. 2022; 1: 56-64
  21. Ларина В.Н., Головко М.Г., Ларин В.Г Влияние коронавирусной инфекции (COVID-19) на сердечно-сосудистую систему. Вестник Российского государственного медицинского университета. 2020; 2: 5-13

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>